This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott (ABT) to Commence Limited Release of EleCare Soon
by Zacks Equity Research
Abbott's (ABT) release of limited quantities of EleCare branded specialty formulas to be free of charge to children in need.
Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable
by Zacks Equity Research
Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.
Abbott (ABT) Down 8.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals
by Zacks Equity Research
Alibaba, McDonald, Advanced Micro Devices, Abbott Laboratories, and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Top Stock Reports for Alibaba, McDonald's & Advanced Micro Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), McDonald's Corporation (MCD), and Advanced Micro Devices, Inc. (AMD).
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Q1 Earnings Scorecard and Analyst Reports for AbbVie, QUALCOMM & Linde
by Sheraz Mian
Today's Research Daily features a real-time update on the Q1 earnings season and new research reports on AbbVie (ABBV), QUALCOMM (QCOM), and Linde(LIN).
3 Medical Product Stocks Set to Beat on Earnings This Season
by Trina Mukherjee
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.
The Zacks Analyst Blog Highlights Visa, Walt Disney, Abbott Laboratories, Nike and United Parcel Service
by Zacks Equity Research
Visa, Walt Disney, Abbott Laboratories, Nike and United Parcel Service have been included in this Analyst Blog.
Top Analyst Reports for Visa, Walt Disney & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), The Walt Disney Company (DIS), and Abbott Laboratories (ABT).
The Zacks Analyst Blog Highlights Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical
by Zacks Equity Research
Alcon, Zimmer Biomet, Cardiovascular Systems, Abbott and Intuitive Surgical have been included in this Analyst Blog.
3 Medical Product Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.
Company News for Apr 21, 2022
by Zacks Equity Research
Companies In The News Are: PG, ABT, ANTM, BKR
Abbott's (ABT) Q1 Earnings and Revenues Exceed Estimates
by Zacks Equity Research
Within Adult Nutrition, Abbott (ABT) gains from the strong performance of Ensure and Glucerna brands in Q1.
Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 17.69% and 7.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Abbott (ABT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Excluding COVID testing sales, Abbott's (ABT) worldwide Diagnostic sales are expected to have demonstrated strong growth in Q1 on the continuous rollout of Alinity, Abbott's suite of diagnostic instruments.
Abbott (ABT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $119.48, moving +0.5% from the previous trading session.
Abbott (ABT) Aveir VR Leadless Pacemaker Receives FDA Nod
by Zacks Equity Research
Abbott's (ABT) Aveir VR is a leadless pacemaker designed to treat patients with slow heart rhythms in the United States.
Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $119.99, marking a +0.87% move from the previous day.
Abbott's (ABT) CGM Device Gets MHLW Nod for Expanded Coverage
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre system will allow diabetics to get the glucose data required to manage their condition without using routine fingersticks.
The Zacks Analyst Blog Highlights Alphabet, Abbott Laboratories, The Charles Schwab, Canadian National Railway Company and Air Products and Chemicals
by Zacks Equity Research
Alphabet, Abbott Laboratories, The Charles Schwab, Canadian National Railway Company and Air Products and Chemicals have been included in this Analyst Blog.